Summary
Robert I. Blum, President and Chief Executive Officer of Cytokinetics Inc (NASDAQ:CYTK), executed an open-market sale of 7,500 common shares on April 15, 2026, at $65.38 per share, for a total of $490,349. Following that disposal, Blum directly owns 415,330 shares of Cytokinetics. Additionally, he holds indirect interests in two Irrevocable Trusts, each with 2,083 shares: The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
Transaction details and ownership
The April 15 sale reduced Blum's direct stake by the quantity reported above while his combined indirect holdings through the two trusts remain at 4,166 shares. The reported per-share price for the transaction was $65.38, and the aggregate value came to $490,349.
Market context
Cytokinetics shares have appreciated sharply over the past year, returning 69.5% and trading near a 52-week peak of $70.98. Independent analysis cited in the reporting indicates the stock appears undervalued at current levels. The reporting also notes availability of comprehensive Pro Research Reports covering CYTK and more than 1,400 other U.S. equities for investors seeking further valuation detail.
Analyst coverage and catalysts
Several sell-side firms have recently updated their views on Cytokinetics. Mizuho raised its price target to $100, citing an extension of intellectual property for aficamten to 2041 and increasing its probability of success for the drug in non-obstructive hypertrophic cardiomyopathy to 75%.
JPMorgan lifted its price target to $75 and kept an Overweight rating, noting a favorable outlook following the approval of Myqorzo for obstructive hypertrophic cardiomyopathy. Evercore ISI reiterated a positive view with an $80 price target, while Stifel reaffirmed its favorable stance and set a $98 target ahead of the Phase 3 ACACIA trial readout, assigning a 70% probability of success based on prior trial data. Leerink Partners maintained an Outperform rating with an $84 target, expressing confidence in the early U.S. launch of Myqorzo and the upcoming ACACIA-HCM Phase 3 results.
Analytical note
The combination of recent analyst target increases, positive probability assessments for clinical programs, and the reported extension of intellectual property for aficamten are highlighted as the primary drivers behind the constructive analyst sentiment reflected in recent coverage. The insider sale and the company’s market performance are presented as contemporaneous developments in the public record.
What remains unchanged in the record
All ownership figures, transaction values, price targets, probability assessments, and trial references above reflect information as reported. No additional claims, dates, or numeric details have been introduced beyond those provided in the public disclosures summarized here.